FDA Drug recall D-0910-2016
LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Continuum Labs, Fort Lauderdale, FL
- FDA Drug
- Class II
- ongoing
- Published 2016-06-08
On 2016-06-08 the FDA classified a Class II recall of LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Continuum Labs, Fort Lauderdale, FL by Invisiblu International, citing marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0910-2016 |
| Classification | Class II |
| Status | ongoing |
| Initiated | 2016-03-31 |
| Published | 2016-06-08 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Invisiblu International |
| Distribution | US |
Product
LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Continuum Labs, Fort Lauderdale, FL
Reason
Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033
Identifiers
| code_info | Lot # 21511166, Exp 11/18 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0910-2016%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.